Nektar TherapeuticsNASDAQ:NKTR
- LAST PRICE1.8050
- TODAY'S CHANGE (%)-0.0250 (-1.3661%)
- Bid / Lots1.8000/ 18
- Ask / Lots1.8100/ 17
- Open / Previous Close1.8300 / 1.8300
- Day Range
- 52 Week Range
- Volume600,578
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NKTR |
|---|---|---|
| 09:32 ET | 33868 | 1.81 |
| 09:34 ET | 9800 | 1.825 |
| 09:36 ET | 8220 | 1.805 |
| 09:38 ET | 2550 | 1.815 |
| 09:39 ET | 11841 | 1.81 |
| 09:41 ET | 4765 | 1.815 |
| 09:43 ET | 22041 | 1.795 |
| 09:45 ET | 11838 | 1.7905 |
| 09:48 ET | 12842 | 1.81 |
| 09:50 ET | 14855 | 1.81 |
| 09:52 ET | 1900 | 1.8089 |
| 09:54 ET | 100 | 1.81 |
| 09:56 ET | 1000 | 1.81 |
| 09:57 ET | 600 | 1.805 |
| 09:59 ET | 3004 | 1.795 |
| 10:01 ET | 1807 | 1.795 |
| 10:03 ET | 313 | 1.795 |
| 10:06 ET | 3905 | 1.8 |
| 10:08 ET | 63461 | 1.795 |
| 10:10 ET | 2060 | 1.795 |
| 10:12 ET | 1354 | 1.7997 |
| 10:14 ET | 1400 | 1.795 |
| 10:15 ET | 920 | 1.795 |
| 10:17 ET | 600 | 1.795 |
| 10:19 ET | 3550 | 1.795 |
| 10:21 ET | 25114 | 1.81 |
| 10:24 ET | 500 | 1.815 |
| 10:26 ET | 130397 | 1.795 |
| 10:28 ET | 25960 | 1.805 |
| 10:30 ET | 15934 | 1.8 |
| 10:32 ET | 7177 | 1.8 |
| 10:33 ET | 1050 | 1.805 |
| 10:35 ET | 2773 | 1.81 |
| 10:37 ET | 12416 | 1.815 |
| 10:39 ET | 2500 | 1.815 |
| 10:42 ET | 500 | 1.815 |
| 10:44 ET | 375 | 1.815 |
| 10:46 ET | 12830 | 1.815 |
| 10:48 ET | 1400 | 1.815 |
| 10:50 ET | 2357 | 1.815 |
| 10:51 ET | 7894 | 1.815 |
| 10:53 ET | 900 | 1.815 |
| 10:55 ET | 6287 | 1.82 |
| 10:57 ET | 12309 | 1.825 |
| 11:00 ET | 200 | 1.825 |
| 11:02 ET | 5056 | 1.825 |
| 11:04 ET | 700 | 1.825 |
| 11:06 ET | 6663 | 1.825 |
| 11:08 ET | 900 | 1.8275 |
| 11:09 ET | 2042 | 1.825 |
| 11:11 ET | 2400 | 1.82 |
| 11:13 ET | 6527 | 1.8112 |
| 11:15 ET | 1001 | 1.8193 |
| 11:18 ET | 3900 | 1.81 |
| 11:20 ET | 300 | 1.815 |
| 11:22 ET | 10898 | 1.805 |
| 11:24 ET | 600 | 1.805 |
| 11:26 ET | 2100 | 1.805 |
| 11:27 ET | 5600 | 1.805 |
| 11:29 ET | 3137 | 1.8 |
| 11:31 ET | 7258 | 1.81 |
| 11:33 ET | 900 | 1.805 |
| 11:36 ET | 2200 | 1.805 |
| 11:38 ET | 2500 | 1.805 |
| 11:40 ET | 900 | 1.805 |
| 11:42 ET | 2076 | 1.805 |
| 11:44 ET | 2100 | 1.805 |
| 11:45 ET | 1300 | 1.805 |
| 11:47 ET | 900 | 1.805 |
| 11:49 ET | 1600 | 1.805 |
| 11:51 ET | 200 | 1.805 |
May 9, 2024
Nektar Therapeutics Reports First Quarter 2024 Financial Results, from 4:15PM ET on Thursday May 09, 2024 by Dow Jones
4:15PM ET on Thursday May 09, 2024 by Dow Jones*DJ Nektar Therapeutics 1Q Loss/Shr 19c >NKTR, from 4:15PM ET on Thursday May 09, 2024 by Dow Jones
4:15PM ET on Thursday May 09, 2024 by Dow Jones
May 2, 2024
Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets, from 6:00PM ET on Thursday May 02, 2024 by Dow Jones
6:00PM ET on Thursday May 02, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Nektar Therapeutics | 336.0M | -2.0x | --- |
Sanara Medtech Inc | 293.7M | -65.2x | --- |
Lifecore Biomedical Inc | 183.0M | -2.8x | --- |
Daiichi Sankyo Co Ltd | 68.3B | 51.8x | --- |
Esperion Therapeutics Inc | 435.8M | -2.4x | --- |
Aquestive Therapeutics Inc | 293.1M | -7.7x | --- |
Company Information
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company. The Company is focused on discovering and developing medicines in the field of immunotherapy. The Company has a research and development pipeline of investigational medicines in immunology and oncology. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its pipeline includes NKTR-255, Rezpegaldesleukin (REZPEG) and NKTR-0165. NKTR-255 is an investigational biologic that is designed to target the interleukin-15 (IL-15) pathway in order to activate the body’s innate and adaptive immunity. Its Rezpegaldesleukin pipeline is an investigational, potential first-in-class T regulatory cell stimulator that addresses this underlying immune system imbalance in people with many autoimmune and inflammatory conditions. Rezpegaldesleukin is being developed as a self-administered injection.
Contact Information
- Headquarters
- 455 Mission Bay Boulevard SouthSAN FRANCISCO, CA, United States 94158
- Phone
- 415-482-5300
- Fax
- 415-339-5300
Executives
- Independent Chairman of the Board
- Robert Chess
- President, Chief Executive Officer
- Howard Robin
- Interim Chief Financial Officer
- Sandra Gardiner
- Senior Vice President, Chief Legal Officer
- Mark Wilson
- Chief Medical Officer
- Mary Tagliaferri
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $336.0M |
|---|---|
Revenue (TTM) | $90.2M |
Shares Outstanding | 183.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.80 |
EPS | $-0.92 |
Book Value | $0.68 |
P/E Ratio | -2.0x |
Price/Sales (TTM) | 3.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -182.33% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
